Feb 25 2026

george

Diagnostic Equity Question: INR is 3.9

This question appeared 2-24-26 on the Diagnostic Equity website: “I’m on warfarin for atrial fibrillation, and my INR today is 3.9. The target range is 2.0–3.0. I haven’t changed my diet or missed any doses. What factors could cause my INR to drift this high unexpectedly, and when does an elevated INR become an emergency?” […]

read more

Comments (0)

Anticoagulant Therapy

Feb 24 2026

george

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

Here is an open-access article contrasting the validity of OSA versus CSA for measuring efanesoctocog alfa (Altuviiio®) spiked into normal plasma: Pipe S, Sadeghi-Khomami A, Konkle BA, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. […]

read more

Comments (0)

Factor Assays

Feb 22 2026

george

JTH Editorial: The Problem With Coagulopathy…

Click here for the open-access editorial Thachil J. The problem with coagulopathy …. J Thromb Haemost. 2022;20:2171-2172. doi: 10.1111/jth.15795. PMID: 35733290. Abstract Coagulopathy is inextricably linked to the field of hemostasis and thrombosis. In the same manner, hemostasis and thrombosis may deal with bleeding and clot formation; coagulopathy also may be connected to bleeding or […]

read more

Comments (0)

Global Hemostasis Assays

Feb 21 2026

george

Review: Non-antithrombotic Strategies for Venous Thromboembolism Prophylaxis

Check with your medical library for this provocative review of VTE prevention: Gurumurthy G, Thachil J. Nonanticoagulant strategies for venous thromboembolism prophylaxis. Semin Thromb Hemost. 2026;52:236–47. doi: 10.1055/a-2712-3534. PMID: 41092960. Abstract Venous thromboembolism (VTE) remains a major cause of preventable morbidity and mortality. Prophylaxis with anticoagulation is limited by bleeding risk, contraindications, and patient-specific factors. […]

read more

Comments (0)

Thrombophilia

Feb 19 2026

george

CAP Today: Hemostasis Testing While on DOACs

This open-access January 26 CAP Today document features the opinions of several experts as they address the limitations of coagulation testing in patients taking DOACs, such as dabigatran, rivaroxaban, or apixaban, and speculates on the coagulation effects of the upcoming anti-XI antithrombotics: Direct Oral Anticoagulants–New Guidance, Lab Testing.

read more

Comments (0)

Anticoagulant Therapy

Feb 17 2026

george

Case: Essential Thrombocythemia

Here is a February 16, 2026, question addressed to the Diagnostic Equity website: “I have essential thrombocythemia (ET). Can I live a normal life, and will my labs be a barometer for how I am doing?” Here is the response excerpted by colleague Kathryn Golab, DCLS: ET is a disorder of the early blood-forming cells […]

read more

Comments (0)

Arterial Thrombosis

Feb 13 2026

george

Letter to 2024 NEJM Links Adenoviral Anti-PF4 to VITT

Click here for the full news release from Flinders University News: New research, led by Flinders University and international experts, has finally uncovered how a rare blood-clotting condition can occur after some COVID-19 adenovirus-based vaccines or after a natural adenovirus infection. First paragraph: To the Editor: Disorders caused by antibodies against platelet factor 4 (PF4) gained […]

read more

Comments (0)

Arterial Thrombosis

Feb 13 2026

george

A History of Russell Viper Venom

Here’s an amusing history of RVV and Dr. Russell, who named the venom. You may retrieve the article from your medical library. Thachil J. Russell viper venom: a journey from the bedside to the bench and back to the bedside. Semin Thromb Hemost. 2024;50:115-118. doi: 10.1055/s-0043-1771269.  PMID: 37506733. Abstract Russell Viper Venom (RVV) is widely […]

read more

Comments (0)

Anticoagulant Therapy

Feb 13 2026

george

What is Red Light Therapy?

Check with your medical library for this in-depth review of red light Rx efficacy: Fan BE, Pasalic L, Hew YY, Lippi G, Favaloro EJ. Red light therapy in thrombosis and hemostasis. Semin Thromb Hemost. 2026;52:266–72. doi: 10.1055/a-2717-5157. PMID: 41062078. Abstract Red light therapy is emerging as a potential non-pharmacological modulator of thrombosis and hemostasis. Photobiomodulation […]

read more

Comments (0)

Antiplatelet Therapy

Feb 9 2026

george

Enhanced Coagulation Potential FVIII

See this open-access article that describes a synthetic enhanced coagulation potential FVIII. This preparation reflects the enhanced activity FIX Padua. Kashiwakura Y, Nakajima Y, Horinaka K, et al. Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy. Blood. 2026;147:402–15. doi: 10.1182/blood.2025028481. PMID: 41198051. Abstract Click here for the visual […]

read more

Comments (0)

Bleeding Disorders